Usefulness of CA 125 as a preoperative prognostic marker for transitional cell carcinoma of the bladder

Journal of Urology

Volumn 172, Issue 6 I, 2004, Pages 2182-2186

  Chang, Andy ^a   Cai, Jie ^a   Miranda, Gus ^a   Groshen, Susan ^a   Skinner, Donald ^a   Stein, John P ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

Bladder; Bladder neoplasms; CA 125 antigen; Carcinoma, transitional cell; Tumor markers, biological

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CYSTECTOMY; FEMALE; HUMAN; LYMPH NODE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA;

EID: 8644287369     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000143487.20280.ed     Document Type: Article

References (13)

1. Stein, J. P., Lieskovsky, G., Cote, R., Groshen, S., Feng, A. C., Boyd, S. et al: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol, 19: 666, 2001
2. Stein, J. P., Grossfeld, G. D., Ginsberg, D. A., Esrig, D., Freeman, J. A., Figueroa, A. J. et al: Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol, 160: 645, 1998
3. Ammon, A., Weber, M. H., Wallner, I., Marschner, N., Droese, M., Grone, H. J. et al: Expression of the tumor-associated glycoproteins MCA, CA 125 and BW 495/36-P in epithelial tumors of the kidney and the urinary bladder. Int J Biol Markers, 9: 224, 1994
4. Ammon, A., Weber, M. H., Wallner, I., Marschner, N., Droese, M., Grone, H. J. et al: Immunocytochemical determination of the tumor-associated glycoproteins MCA, CA 125 and BW 495/36-P in urine of patients with epithelial tumors of the kidney and urinary bladder. Int J Biol Markers, 10: 17, 1995
5. Izes, J. K., Dyer, M. W., Callum, M. G., Bankes, P., Libertino, J. A., Caffrey, J. A. M.: Ca 125 as a marker of tumor activity in advanced urothelial malignancy. J Urol, 165: 1908, 2001
6. Bast, R. C., Jr., Klug, T. L., St John, E., Jenison, E., Niloff, J. M., Lazarus, H. et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med, 309: 883, 1983
7. Bergkvist, A., Ljungqvist, A. and Moberger, G.: Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand, 130: 371, 1965
8. Fleming, I. D., Cooper, J. S., Henson, D. E., Hutter, R. V. P., Kennedy, B. J., Murphy, G. P. et al: AJCC Cancer Staging Manual, 5th ed. Philadelphia: Lippincott-Raven Publishers, 1997
9. Tuxen, M. K., Soletormos, G. and Dombernowsky, P.: Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev, 21: 215, 1995
10. Evans, A. C., Jr. and Berchuck, A.: Tumor markers. In: Principles and Practice of Gynecologic Oncology, 2nd ed. Edited by W. J. Hoskins, C. A. Perez and R. C. Young. Philadelphia: Lippincott-Raven Publishers, chapt. 7, pp. 177-195, 1997
11. Herbst, A. L.: The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am J Obstet Gynecol, 170: 1099, 1994
12. Erickson, D. R., Dabbs, D. J. and Olt, G. J.: Transitional cell bladder carcinoma with presentation mimicking ovarian carcinoma. Gynecol Oncol, 61: 294, 1996
13. Malkowicz, S. B.: Superficial bladder cancer: the role of molecular markers in the treatment of high-risk superficial disease. Semin Urol Oncol, 15: 169, 1997